SCHEMBL620753

SCHEMBL620753

COc1cc2cc(O)cnc2cc1F

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 19/20 0.52
PDGFRA P16234 19/20 0.52
PDE10A Q9Y233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401408 0.86 PDGFRB (0.66) PDGFRBPDGFRA
SCHEMBL3877724 0.83 PDGFRB (0.55) PDGFRBPDGFRA
SCHEMBL622733 0.80 PDGFRB (0.52) PDGFRBPDGFRA
SCHEMBL3214568 0.80 PDGFRB (0.52) PDGFRBPDGFRA
SCHEMBL3873425 0.77 HPGDS (0.58) PDGFRBPDGFRA
SCHEMBL28264937 0.76 HPGDS (0.56) PDGFRBPDGFRA
SCHEMBL18318550 0.73 PDGFRB (0.52) PDGFRBPDGFRA
SCHEMBL324131 0.72 CYP3A4 (0.46) PDGFRBPDGFRA
SCHEMBL19020776 0.72 PDGFRB (0.56) PDGFRBPDGFRA
SCHEMBL31391357 0.71 ALDH1A1 (0.49) PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133219-B2 Bicyclic antibiotics BASILEA PHARMACEUTICA AG (CH) 2015-09-15 US disclosed
US-20150080373-A1 NOVEL BICYCLIC ANTIBIOTICS Basiliea Pharmaceutica AG 2015-03-19 US disclosed
US-8927542-B2 Bicyclic antibiotics BASILEA PHARMACEUTICA AG (CH) 2015-01-06 US disclosed
US-20140221348-A1 NOVEL BICYCLIC ANTIBIOTICS BASILEA PHARMACEUTICA AG (CH) 2014-08-07 US disclosed
US-8716280-B2 Bicyclic antibiotics BASILEA PHARMACEUTICA AG (CH) 2014-05-06 US disclosed
US-20120040957-A1 Novel Bicyclic Antibiotics BASILEA PHARMACEUTICA AG 2012-02-16 US disclosed
EP-2389376-A1 NOVEL BICYCLIC ANTIBIOTICS Basilea Pharmaceutica AG (CH) 2011-11-30 EP disclosed
WO-2010084152-A1 NOVEL BICYCLIC ANTIBIOTICS BASILEA PHARMACEUTICA AG (CH) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040957-A1 Novel Bicyclic Antibiotics C5, C1S, CBR3 PDGFRB 4750/4885PDGFRA 4741/4885PDE10A 3632/4885
US-20140221348-A1 NOVEL BICYCLIC ANTIBIOTICS C1S, XPA, XDH PDGFRB 4785/4885PDGFRA 4737/4885PDE10A 2898/4885
US-20150080373-A1 NOVEL BICYCLIC ANTIBIOTICS C1S, XPA, XDH PDGFRB 4785/4885PDGFRA 4737/4885PDE10A 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.